Abstract: [Abstract] Objective: In recent years there have been research reports indicate that paclitaxel oxaliplatin can improve the efficiency of advanced gastric cancer and survival, adverse reactions can be tolerated. And oxaliplatin combination with fluorouracil have synergistic effects. This group of paclitaxel, oxaliplatin, fluorouracil is in the treatment of advanced gastric cancer, aims to explore the Clinical efficacy of advanced gastric cancer and adverse reactions. Methods: Undergraduate from January 2005 to January 2010, 94 advanced gastric cancer patients were enrolled. Chemotherapy dose and method of setting: paclitaxel (PTX )135 mg/m2 d1, fluorouracil (5-Fu) 500 mg/m2, intravenous continuous infusion chemotherapy pump d2-6, oxaliplatin 100mg/m2, intravenously 3h, d2. strict accordance with the instructions before using paclitaxel pretreatment. 21 days for one cycle, two cycles were evaluated.. Results: Whole group of 94 patients total effective rate was 52.1% (49/94), complete response rate was 1.0% (1 / 94), partial remission rate was 51.1% (48/94), stable was 23.4% (22/94) , progress was 24.5% (23/94). The median time to progression was 7.2 months, median survival time of 11.3 months. No treatment-related deaths, mainly in peripheral blood cells to decrease toxicity, gastrointestinal reactions, alopecia and peripheral neurotoxicity..Conclusions: Paclitaxel, oxaliplatin, fluorouracil in the treatment of advanced gastric cancer is effective, patients can delay disease progression, and toxicity can be tolerated, has clinical value.

Key words: Advanced gastric cancer, paclitaxel, oxaliplatin, fluorouracil, combination chemotherapy